Kopran Ltd

AGM Details

• 67th AGM held on 18 Aug 2026 via VC/OAVM from 11:30 AM to 12:00 PM.
• 39 Members attended the AGM virtually.
• Remote and AGM e-voting used; results announced.
• Cut-off date for voting: Aug 11, 2026.

Resolutions

• Resolution 1 (Ordinary): Audited financial statements for year ended March 31, 2026 approved.
• Resolution 2 (Ordinary): Audited consolidated financial statements for year ended March 31, 2026 approved.
• Resolution 3 (Ordinary): Dividend on equity shares for year ended March 31, 2026 approved.
• Resolution 4 (Ordinary): Re-appointment of Varun Somani as Director.
• Resolution 5 (Ordinary): Appointment of Namrata Somani as Director.

Dividend

• Final dividend of Rs 3.00 per equity share approved.

Director changes

• Varun Somani retires by rotation; re-appointed as Director.
• Namrata Somani appointed as Director.

Business Overview

• Integrated pharma company with Formulations and API verticals.
• API operations run via KRLL, Kopran's wholly owned subsidiary.
• Export reach spans 50+ countries with focus on regulated and non-regulated markets.
• Regulatory accreditations in key markets support global manufacturing.

Operational Highlights

• Q1 2026-27 revenue ₹153.99 crore; EBITDA ₹15.88 crore; net profit ₹6.70 crore.
• EBITDA margin for Q1 2026-27: 10.31%.
• FY2025-26 revenue ₹681.42 crore; net worth ₹537.09 crore.
• Borrowings ₹166.87 crore; fixed assets ₹377.80 crore.
• Sales/Other Income in Q1 2026-27 ₹156.05 crore.

Financial Performance

• FY2025-26: Revenue ₹681.42 crore; EBITDA ₹78.25 crore; Net profit ₹25.73 crore.
• Q1 2026-27: Revenue ₹153.99 crore; EBITDA ₹15.88 crore; Net profit ₹6.70 crore.
• EBITDA margin: Q1 10.31%; FY2025-26 11.48%.
• Equity capital ₹48.29 crore; Net worth ₹537.09 crore.

Capital Structure & Liquidity

• Borrowings rose to ₹166.87 crore in Q1 2026-27 from ₹152.69 crore.
• Equity capital ₹48.29 crore; Net worth ₹537.09 crore.
• No credit rating or explicit liquidity metrics disclosed in this chunk.

Strategic Priorities & Outlook

• R&D focus on niche, high-value APIs and intermediates.
• Capacity expansion to support growth.
• Move toward self-sufficiency; reduce dependence on China.
• Leverage API-formulations synergies; pursue new regulatory filings and registrations.
• Export reach to 50+ countries to drive growth.

Risks & Mitigation

• Regulatory and API/formulation business risks.
• Mitigation: strengthen regulatory compliance, expand capacity, and invest in R&D.

Governance & Leadership

• Chairman and MD: Surendra Somani.
• Independent directors: Chandresh Gandhi, Mamta Biyani, Narayan Atal.
• Other directors: Varun Surendra Somani, Namrata Somani.

Financial results approved

• Unaudited standalone and consolidated results for quarter ended 30 June 2026 approved.
• Audit Committee reviewed; Board approved on August 7, 2026.

Auditor reports and disclosures

• Statutory auditors expressed unmodified opinions on standalone and consolidated results.
• Limited Review Reports prepared under Ind AS 34.
• Auditors note two subsidiaries' interim results were not reviewed; impact not material.

Other material disclosures

• No separate reportable segments; Group operates in Pharmaceuticals.
• Results prepared in accordance with Ind AS; no minority interest.

Financial snapshot (Standalone)

• Standalone revenue ₹30,765 L; net profit ₹3,040 L; OCI ₹31 L; total OCI ₹3,071 L.
• Standalone EBITDA ₹7,790 L; RoE 4.9%; RoCE 9.2%; EPS ₹5.33.
• Formulations revenue ₹30,565 L; API revenue ₹37,760 L; total standalone revenue.
• Formulations grew 12.78% YoY; API grew 3.49%.
• Panoli API facility commenced production year-end.
• ESOP 2023: 4,75,000 options approved; 1,37,700 outstanding.
• Dividend proposed ₹3 per share (30%); payable if approved.

Consolidated performance

• Consolidated revenue ₹68,177 L; PAT ₹2,573 L; OCI ₹51.85 L; total OCI ₹2,625 L.
• Consolidated EBITDA ₹6,195 L; PBT ₹3,435.6 L; PAT ₹2,573 L.
• Subsidiaries include Kopran Research Laboratories Limited, Kopran Lifesciences Limited, Kopran HK, Kopran UK.

Dividends & ESOP

• Dividend: ₹3 per share (30%) for FY2025-26.
• Dividend payable within 30 days of declaration; cash outflow ~₹1,448.57 L.
• ESOP 2023: 4,75,000 options; 1,37,700 outstanding.

Capital structure & liquidity

• Total borrowings: current ₹13,874.4 L; non-current ₹1,394.8 L.
• Net debt ₹15,201.05 L; gearing 22.28%.
• Cash and cash equivalents ₹68.2 L at year-end.
• Operating cash flow ₹6,675 L; investing cash flow ₹-6,459.85 L; financing ₹-2,094.30 L.

Governance & risk

• Board: 5 directors; Susheel Somani and Adarsh Somani resigned; Namrata Somani appointed 19-05-2026.
• Auditors: KL - Khandelwal Jain; KRLL - NGS & Co; Secretarial - Smita Prabhu; no qualifications.
• Board committees: AC, NRC, SRC, CSR, RMC, CAC; independence maintained.
• Directors' responsibility: going concern; compliance with law; no fraud observed.

CSR & ESG

• CSR spend ₹83.53 L; CSR obligation ₹60.55 L; shortfall ₹23.40 L.
• CSR activities include health, education, environment; eight projects.
• CSR policy hosted on company website; carry-forward of shortfall as applicable.

Subsidiaries & group

• Subsidiaries: Kopran Research Laboratories Limited; Kopran Lifesciences Limited.
• Overseas subsidiaries: Kopran (HK) Limited; Kopran (UK) Limited.

Outlook & strategy

• Outlook: deepen API backward integration.
• Expand CDMO/CMO; Panoli API and R&D expansion; grow exports.

Record Date for Dividend

• Record date for dividend payment: Tuesday, August 11, 2026 (subject to TDS).
• Dividend will be paid if declared at the AGM on Tuesday, August 18, 2026.
• The security type is equity shares.

Dematerialisation status

• Dematerialisation requests up to period end were processed and confirmed to depositories.
• Securities dematerialised have been listed on the stock exchanges.
• Physical certificates for dematerialisation were mutilated and cancelled; depository owner updated within 15 days.